|
| 36920594 | Adjusting the Use of Glucose-Lowering Agents in the Real-World Clinical Management of People with Type 2 Diabetes: A Narrative Review. | | 2023 |
| 37435776 | Effects of sodium-glucose co-transporter-2 inhibitors by background cardiovascular medications: A systematic review and meta-analysis. | | 2023 |
| 34545668 | Sotagliflozin for patients with type 2 diabetes: A systematic review and meta-analysis. | Diabetes, Obesity and Metabolism | 2022 |
| 35579691 | Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis. | Diabetologia | 2022 |
| 33826709 | Effects of canagliflozin on myocardial infarction: a post hoc analysis of the CANVAS programme and CREDENCE trial. | Cardiovasc Res | 2022 |
| 34448881 | Correction to: Polygenic risk scores predict diabetes complications and their response to intensive blood pressure and glucose control. | Diabetologia | 2021 |
| 33705820 | GLP-1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: A systematic review and meta-analysis. | Diabetes Research and Clinical Practice | 2021 |
| 34226943 | Polygenic risk scores predict diabetes complications and their response to intensive blood pressure and glucose control. | Diabetologia | 2021 |
| 34047443 | Comparative efficacy of glucose-lowering medications on body weight and blood pressure in patients with type 2 diabetes: A systematic review and network meta-analysis. | Diabetes, Obesity and Metabolism | 2021 |
| 34105242 | Ultra-rapid-acting insulins for adults with diabetes: A systematic review and meta-analysis. | Diabetes, Obesity and Metabolism | 2021 |
| 32979427 | An exploration of the heterogeneity in effects of SGLT2 inhibition on cardiovascular and all-cause mortality in the EMPA-REG OUTCOME, CANVAS Program, DECLARE-TIMI 58, and CREDENCE trials. | Int J Cardiol | 2021 |
| 33300282 | Comparative efficacy and safety of glucose-lowering drugs as adjunctive therapy for adults with type 1 diabetes: A systematic review and network meta-analysis. | Diabetes, Obesity and Metabolism | 2021 |
| 32971190 | Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program. | Am J Kidney Dis | 2021 |
| 32894637 | Early combination therapy delayed treatment escalation in newly diagnosed young-onset type 2 diabetes: A subanalysis of the VERIFY study. | Diabetes, Obesity and Metabolism | 2021 |
| 34402161 | Reasons for hospitalizations in patients with type 2 diabetes in the CANVAS programme: A secondary analysis. | Diabetes Obes Metab | 2021 |
| 32691499 | Effects of canagliflozin on initiation of insulin and other antihyperglycaemic agents in the CANVAS Program. | Diabetes Obes Metab | 2020 |
| 32250523 | ADVANCE. | Diabetes, Obesity and Metabolism | 2020 |
| 31637820 | Oral semaglutide for type 2 diabetes: A systematic review and meta-analysis. | Diabetes, Obesity and Metabolism | 2020 |
| 31729107 | Clinical outcomes with canagliflozin according to baseline body mass index: results from post hoc analyses of the CANVAS Program. | Diabetes Obes Metab | 2020 |
| 32405783 | Prevention and management of COVID-19 among patients with diabetes: an appraisal of the literature. | Diabetologia | 2020 |
| 31676303 | Mediators of the Effects of Canagliflozin on Heart Failure in Patients With Type 2 Diabetes. | JACC Heart Fail | 2020 |
| 32598218 | Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes: A Systematic Review and Network Meta-analysis. | Annals of Internal Medicine | 2020 |
| 32975711 | Insights from VERIFY: Early Combination Therapy Provides Better Glycaemic Durability Than a Stepwise Approach in Newly Diagnosed Type 2 Diabetes. | Diabetes Therapy | 2020 |
| 32694216 | Different eGFR Decline Thresholds and Renal Effects of Canagliflozin: Data from the CANVAS Program. | J Am Soc Nephrol | 2020 |
| 30882240 | Effects of Canagliflozin on Heart Failure Outcomes Associated With Preserved and Reduced Ejection Fraction in Type 2 Diabetes Mellitus. | Circulation | 2019 |
| 30591006 | Canagliflozin and Stroke in Type 2 Diabetes Mellitus. | Stroke | 2019 |
| 30058208 | Glucagon-like peptide-1 receptor agonists and microvascular outcomes in type 2 diabetes: A systematic review and meta-analysis. | Diabetes, Obesity and Metabolism | 2019 |
| 30576013 | Baseline characteristics in the VERIFY study: a randomized trial assessing the durability of glycaemic control with early vildagliptin-metformin combination in newly diagnosed Type 2 diabetes. | Diabetic Medicine | 2019 |
| 30226298 | Worsening of diabetic retinopathy with rapid improvement in systemic glucose control: A review. | Diabetes, Obesity and Metabolism | 2019 |
| 30037759 | Among young Sri Lankan patients with diabetes, how do lipid profiles differ between those with and without metabolic syndrome? | Diabetes and Metabolic Syndrome: Clinical Research and Reviews | 2019 |
| 31530577 | Effect of Canagliflozin on Renal and Cardiovascular Outcomes across Different Levels of Albuminuria: Data from the CANVAS Program. | J Am Soc Nephrol | 2019 |
| 31144427 | A pre-specified statistical analysis plan for the VERIFY study: Vildagliptin efficacy in combination with metformin for early treatment of T2DM. | Diabetes, Obesity and Metabolism | 2019 |
| 31542292 | Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. | Lancet, The | 2019 |
| 30868176 | Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program. | Diabetologia | 2019 |
| 30758834 | The Standard of Care in Type 2 Diabetes: Re-evaluating the Treatment Paradigm. | Diabetes Therapy | 2019 |
| 31399845 | Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program. | Diabetologia | 2019 |
| 29802958 | The place of gliclazide MR in the evolving type 2 diabetes landscape: A comparison with other sulfonylureas and newer oral antihyperglycemic agents. | Diabetes Research and Clinical Practice | 2018 |
| 30354619 | Letter by Matthews et al Regarding Article, "Class Effect for Sodium Glucose-Cotransporter-2 Inhibitors in Cardiovascular Outcomes: Implications for the Cardiovascular Disease Specialist". | Circulation | 2018 |
| 29987326 | Comparative Benefits and Harms of Basal Insulin Analogues for Type 2 Diabetes: A Systematic Review and Network Meta-analysis. | Annals of Internal Medicine | 2018 |
| 29941478 | Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function. | Circulation | 2018 |
| 29937267 | Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials. | Lancet Diabetes Endocrinol | 2018 |
| 29756388 | Semaglutide for type 2 diabetes mellitus: A systematic review and meta-analysis. | Diabetes, Obesity and Metabolism | 2018 |
| 29526832 | Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program. | Circulation | 2018 |
| 29178519 | Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy. | Diabetes, Obesity and Metabolism | 2018 |
| 29133604 | Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study). | Circulation | 2018 |
| 29429894 | Prevalence, patterns, and associations of dyslipidemia among Sri Lankan adults-Sri Lanka Diabetes and Cardiovascular Study in 2005-2006. | Journal of Clinical Lipidology | 2018 |
| 29079715 | Changes in Albuminuria and the Risk of Major Clinical Outcomes in Diabetes: Results From ADVANCE-ON. | Diabetes Care | 2018 |
| 28244644 | Optimizing the analysis strategy for the CANVAS Program: A prespecified plan for the integrated analyses of the CANVAS and CANVAS-R trials. | Diabetes Obes Metab | 2017 |
| 28605608 | Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. | N Engl J Med | 2017 |
| 28448177 | Once-weekly dipeptidyl peptidase-4 inhibitors for type 2 diabetes: a systematic review and meta-analysis. | Expert Opinion on Pharmacotherapy | 2017 |